| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
3',4',7-Trimethoxyquercetin modulates key signaling pathways including NF-κB and PI3K/Akt, contributing to cellular protection and immune regulation. It also modulates the MAPK/ERK pathway, which is crucial for cell proliferation and differentiation. As a polymethoxyflavonoid, its targets include inflammatory mediators such as IL-6, with demonstrated suppression of LPS-induced IL-6 production in mouse J774.A1 cells. The compound's antioxidant activity involves scavenging free radicals and reducing oxidative stress in cellular models. Its anticancer activity is mediated through modulation of survival and proliferation pathways. The compound's increased lipophilicity due to methylation may enhance its interactions with cellular membranes and targets.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that 3',4',7-Trimethoxyquercetin exhibits anti-inflammatory activity in mouse J774.A1 cells with an IC50 of 22.9 μM for suppression of LPS-induced IL-6 production as measured by ELISA. At concentrations of 1-10 μM for 3 hours, the compound shows activity in MCF-7 breast cancer cells. The compound displays antioxidant properties through free radical scavenging mechanisms. Its anticancer activity has been demonstrated in various cancer cell lines. The compound's ability to modulate NF-κB and PI3K/Akt pathways contributes to its anti-inflammatory and cytoprotective effects in vitro. These in vitro findings support its potential in therapeutic and nutraceutical development.
|
| ln Vivo |
In vivo studies of 3',4',7-Trimethoxyquercetin are limited as the compound is primarily used as a research chemical. As a methylated flavonol derivative, it is expected to have enhanced metabolic stability and bioavailability compared to quercetin, potentially allowing for better systemic exposure in vivo. The compound's anti-inflammatory and antioxidant activities suggest potential for in vivo evaluation in models of inflammation and oxidative stress. Its anticancer activity indicates potential for evaluation in tumor models. However, comprehensive in vivo pharmacological studies are not well documented in the available literature. The compound is intended for research use only and is not for human therapeutic use.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 3',4',7-Trimethoxyquercetin typically involve testing its anti-inflammatory activity through suppression of LPS-induced IL-6 production. Mouse J774.A1 cells are stimulated with LPS and treated with varying concentrations of the compound (with an IC50 of 22.9 μM), and IL-6 levels are measured by ELISA. For antioxidant activity, cell-free systems such as DPPH radical scavenging assays, ABTS assays, or ferric reducing antioxidant power (FRAP) assays are employed. Kinase inhibition assays may be performed to evaluate modulation of NF-κB, PI3K/Akt, and MAPK/ERK pathways. All assays are performed with appropriate controls and standardized protocols to ensure reproducibility of results.
|
| Cell Assay |
In vitro cell-based assays for 3',4',7-Trimethoxyquercetin involve culturing cell lines such as mouse J774.A1 macrophages to evaluate anti-inflammatory activity. Cells are treated with varying concentrations of the compound (1-10 μM for 3 hours) and stimulated with LPS. IL-6 production is measured by ELISA. For anticancer studies, cancer cell lines such as MCF-7 are treated with the compound and cell viability is assessed using MTT or similar colorimetric assays. Cell viability is assessed to ensure that observed effects are not due to cytotoxicity. All experiments are performed in triplicate with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo animal experiments for 3',4',7-Trimethoxyquercetin would be conducted to evaluate its anti-inflammatory, antioxidant, and anticancer activities. For anti-inflammatory studies, animals with induced inflammation would be treated with the compound and inflammatory markers measured. For antioxidant studies, animals would be administered the compound and markers of oxidative stress measured in blood and tissue samples. For anticancer studies, tumor-bearing animals would be treated and tumor growth monitored. Parameters assessed would include body weight, organ weights, inflammatory markers, and histopathology. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines. Comprehensive in vivo studies are not well documented in the available literature.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 3',4',7-Trimethoxyquercetin reflect its nature as a methylated flavonol derivative. It has a molecular weight of 344.32 and the molecular formula C18H16O7. The methoxy groups at the 3', 4', and 7 positions confer increased lipophilicity and metabolic stability compared to quercetin, which may enhance oral absorption and systemic bioavailability. The compound is expected to be metabolized through standard xenobiotic pathways in the liver, including demethylation and conjugation reactions. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies using appropriate analytical methods such as high-performance liquid chromatography-mass spectrometry.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 3',4',7-Trimethoxyquercetin has been evaluated in the context of its use as a research chemical. As a methylated flavonol derivative of quercetin, it is expected to have a favorable safety profile at research concentrations. The compound's anti-inflammatory and antioxidant activities suggest potential for beneficial effects. However, as with all research chemicals, proper handling procedures including use of personal protective equipment are recommended. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile for pharmaceutical applications.
|
| References | |
| Additional Infomation |
Quercetin 7,3',4'-trimethyl ether is a trimethoxyflavonoid, a 7,3',4'-trimethyl ether derivative of quercetin. It has been isolated from Euodia confusa. It is both a metabolite and a plant metabolite. It is a dihydroxyflavonoid, belonging to the flavonol, trimethoxyflavon, and 3'-methoxyflavonoid classes. Its function is related to that of quercetin. Quercetin 7,3',4'-trimethyl ether has also been reported in Aeonium arboreum, Viscum coloratum, and several other organisms with relevant data.
3',4',7-Trimethoxyquercetin (CAS# 6068-80-0) is also known as Quercetin 3',4',7-trimethyl ether and 2-(3,4-dimethoxyphenyl)-3,5-dihydroxy-7-methoxychromen-4-one. It has a purity of ≥95%. The compound is a polymethoxyflavonoid that can be isolated from Taraxacum mongolicum and Scutellaria baicalensis. It is a derivative of quercetin hydrate and exhibits anti-tumor activity. The compound modulates key signaling pathways including NF-κB, PI3K/Akt, and MAPK/ERK. It displays antioxidant, anti-inflammatory, anticancer, and neuroprotective effects. The compound is intended for research use only and is not for human therapeutic use. |
| Molecular Formula |
C18H16O7
|
|---|---|
| Molecular Weight |
344.32
|
| Exact Mass |
344.09
|
| CAS # |
6068-80-0
|
| PubChem CID |
5748558
|
| Appearance |
White to off-white solid
|
| LogP |
2.897
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
532
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)OC)O)O)OC
|
| InChi Key |
OEEUHNAUMMATJT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H16O7/c1-22-10-7-11(19)15-14(8-10)25-18(17(21)16(15)20)9-4-5-12(23-2)13(6-9)24-3/h4-8,19,21H,1-3H3
|
| Chemical Name |
2-(3,4-dimethoxyphenyl)-3,5-dihydroxy-7-methoxychromen-4-one
|
| Synonyms |
Quercetin 3′,4′,7-trimethyl ether; 3',4',7-Trimethoxyquercetin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9043 mL | 14.5214 mL | 29.0428 mL | |
| 5 mM | 0.5809 mL | 2.9043 mL | 5.8086 mL | |
| 10 mM | 0.2904 mL | 1.4521 mL | 2.9043 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
